Journal News

JBC: A causal gene for X-linked intellectual disability

Dawn Hayward
June 1, 2017

Intellectual disability affects between 1 percent and 3 percent of the world’s population. People with X-linked intellectual disability, a heritable condition, present with IQs below 70 and can be mildly or severely handicapped, requiring lifelong care.

The Human Genome Project greatly has facilitated the diagnosis of XLID, and more than 120 genes on the X chromosome have been established as causal for the disease, which primarily affects males.

A recent study in the Journal of Biological Chemistry reports a new causal gene for XLID. The study was conducted by a team of scientists led by Charles Schwartz at the Greenwood Genetic Center in South Carolina and Lance Wells at the University of Georgia.

The family

JBC-A-causal-gene-x-linked-Thumb480x270.png Greenwood Genetic Center

The Greenwood Genetic Center serves patients with birth defects, intellectual disability and autism. There, the Schwartz laboratory works with families with histories of XLID and analyzes genetic defects associated with the disease. For the study published in JBC, individuals from the genetics center traveled to Utah to obtain blood samples from a family with members with XLID in order to isolate DNA and generate cell lines.

DNA sequencing of affected family members uncovered many genes with single-nucleotide changes residing on the X chromosome. After looking for variants that resided in the coding region and that resulted in corresponding amino-acid changes, the Schwartz group came across a mutation in an enzyme called O-GlcNAc transferase, or OGT.

The OGT gene variant found in the Utah family had the three characteristics necessary for continued study: It segregated with the disease, contained a single amino-acid change in the protein and was expressed in the brain. That’s when the collaboration with glycobiologist Wells became critical.

The enzymes

OGT is an enzyme that adds a sugar molecule — GlcNAc — to nuclear and cytosolic proteins. Wells’ group studies this glycosylation modification. The enzyme that removes GlcNAc is called O-GlcNAcase, or OGA. Together, OGT and OGA influence the activity of many cytoplasmic and nuclear proteins in the cell.

The Utah family’s variant contained a leucine-to-phenylalanine substitution, which can be difficult for a protein to accommodate given that phenylalanaine is larger than leucine. The substitution resides in a region of OGT responsible for protein-protein interactions.

Biochemical experiments spearheaded by first author Krithika Vaidyanathan in the Wells laboratory revealed the Utah family’s mutant to be unstable. However, its enzymatic activity was normal, and O-GlcNAc levels, surprisingly, remained constant in patient cell lines derived from blood samples. These findings prompted studies of OGA, the enzyme responsible for removing the modification.

The researchers found that the OGT variant in affected males, along with other co-repressor proteins, occupy the promoter region of the OGA gene and reduce its transcription. This compensates for the OGT variant’s instability and maintains the O-GlcNAc glycosylation modification level.

The Wells laboratory then wondered if the OGT variant occupied other promoter regions too. So the group sequenced RNA of affected males to see which genes’ expression differed from controls’. The researchers found significant changes in several genes, and they’re currently investigating them.

The takeaways

Schwartz notes that the Utah family’s OGT gene variant was challenging to narrow down in the beginning of the work and emphasizes that the collaboration with Wells was critical to establishing OGT’s importance.

Wells points out that the RNA-sequencing experiment involved related patients, which raised the possibility of the results segregating by generation instead of disease. Fortunately, this was not the case.

The researchers say their future studies will investigate additional OGT gene mutations, recently identified by Schwartz and other clinical geneticists, that segregate with the disease. Both the Wells and Schwartz labs are looking at their effects on OGT function. The researchers also are studying stem-cell-derived neuronal cells that are affected by OGT gene mutations.

In the end, the JBC study represents the first instance of an OGT gene mutation being responsible for XLID and broadens the pathways involved in brain development and cognitive function.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Dawn Hayward

Dawn Hayward earned a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Catching tau in the act
Journal News

Catching tau in the act

April 2, 2026

Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.

How copper delivery fuels bacterial respiration
Journal News

How copper delivery fuels bacterial respiration

April 1, 2026

Researchers identify the roles of several proteins in copper homeostasis in the aerobic bacterium Caulobacter vibrioides.

Revealing the glycoproteome of a cancer subtype
Journal News

Revealing the glycoproteome of a cancer subtype

March 31, 2026

Researchers mapped the glycoproteome of extrahepatic cholangiocarcinoma and compared it to intrahepatic tumors. Differences in sugar modifications and immune cell content suggest new biomarkers and guide development of targeted immunotherapies.

Uncovering the mechanisms of a glycosylation disorder
Journal News

Uncovering the mechanisms of a glycosylation disorder

March 27, 2026

Mutations in OGT, an enzyme that adds sugars to proteins, cause a rare neurological disorder. Using proteomics, researchers reveal how OGT interactions with TET proteins may trigger epigenetic changes and early neural defects.

Heat shock proteins as a promising breast cancer therapeutic
Journal News

Heat shock proteins as a promising breast cancer therapeutic

March 25, 2026

Researchers unveiled isoform-specific targets on heat shock protein 90 which may be beneficial in therapeutic development.

Optimized proteomic analysis of preserved biological tissue samples
Journal News

Optimized proteomic analysis of preserved biological tissue samples

March 25, 2026

Researchers have developed an optimized workflow for analyzing formalin-fixed paraffin-embedded tissue. This workflow provides an enhanced collection of unique proteins and phosphorylation sites for more detailed analysis of biological samples.